ICON plc (ICLR) : 5 brokerage houses believe that ICON plc (ICLR) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ICON plc (ICLR). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 10 Wall Street Analysts endorse the stock as a Buy with a rating of 2.2.
ICON plc (ICLR) : The consensus price target for ICON plc (ICLR) is $78 for the short term with a standard deviation of $11.31. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $87, however, the pessimist price target for the company is $59.
Shares of ICON Public Limited Company rose by 1.69% in the last five trading days and 8.03% for the last 4 weeks. ICON Public Limited Company is up 14.11% in the last 3-month period. Year-to-Date the stock performance stands at -0.99%. ICON plc (NASDAQ:ICLR): stock turned positive on Tuesday. Though the stock opened at $76.58, the bulls momentum made the stock top out at $77.23 level for the day. The stock recorded a low of $76.58 and closed the trading day at $76.93, in the green by 0.63%. The total traded volume for the day was 161,273. The stock had closed at $76.45 in the previous days trading.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.